Last Update Time:
28-Feb-2025 16:00:00
ISIN:
INE742B01025
Sector:
Healthcare
Symbol:
GUFICBIO
Gufic Biosciences Limited
₹333.00
₹-2.45
(-0.73%)
▼
Prev. Close
₹335.45
Open
₹332.75
Close
₹330.55
Range
₹316.35 - ₹349.65
High
₹338.00
Low
₹320.00
Ind. Close
₹0.00
VWAP
₹328.48
The current stock price of Gufic Biosciences Limited is ₹333.00, with a target price range between ₹316.35 and ₹349.65. The stock has experienced a price change of ₹-2.45 (-0.73%), reflecting recent market volatility.
Today's opening price was ₹332.75, while the previous close stood at ₹335.45.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Gufic Biosciences Limited Price Chart
Gufic Biosciences Limited Pre Open Market Overview: 28-Feb-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 332.75
- Previous Close Price: 335.45
- Change: -2.70%
- Total Traded Volume: 389
- Total Buy Quantity: 1,453
- Total Sell Quantity: 4,359
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 323.30 | 10.00 | 0.00 |
| 325.00 | 2.00 | 0.00 |
| 325.35 | 2.00 | 0.00 |
| 325.50 | 10.00 | 0.00 |
| 330.00 | 2.00 | 0.00 |
| 332.75 | 0.00 | 686.00 |
| 332.80 | 0.00 | 200.00 |
| 332.90 | 0.00 | 100.00 |
| 334.00 | 0.00 | 100.00 |
| 335.30 | 0.00 | 100.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1453
Total Sell Quantity: 4359
Shareholding Patterns of Gufic Biosciences Limited
Key Trade Statistics of Gufic Biosciences Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.60 |
| Traded Value (₹ Cr.) | 1.97 |
| Total Market Cap (₹ Cr.) | 3,339.24 |
| Free Float Market Cap (₹ Cr.) | 893.21 |
| Impact cost | 0.16 |
| Quantity Traded | 59,981.00 |
| Deliverable Quantity | 28,720.00 |
| % of Quantity to Traded | 47.88 |
| Security VaR | 17.27 |
| Index VaR | N/A |
| VaR Margin | 17.27 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 20.77 |
| Face Value | 1 |
Key Price Statistics of Gufic Biosciences Limited
The 52-week high for Gufic Biosciences Limited was ₹504.25, recorded on 08-Nov-2024. On the other hand, the 52-week low stands at ₹277.65, with the lowest value recorded on 15-Mar-2024.
The upper band for trading is ₹402.50, and the lower band is ₹268.40. The price band is 20%.
The stock's daily volatility stands at 2.65, while the annualized volatility is 50.63. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (08-Nov-2024) | 504.25 |
| 52 Week Low (15-Mar-2024) | 277.65 |
| Upper Band | 402.50 |
| Lower Band | 268.40 |
| Price Band (%) | 20 |
| Daily Volatility | 2.65 |
| Annualised Volatility | 50.63 |
| Tick Size | 0.05 |
Key Securities Statistics of Gufic Biosciences Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 19-Oct-2004 |
| Adjusted P/E | 40.44 |
| Symbol P/E | 40.44 |
| Index | NA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Gufic Biosciences Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Gufic Biosciences Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 21-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 20-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 17-Feb-2025 |
| Copy of Newspaper Publication | 15-Feb-2025 |
| Integrated Filing- Financial | 14-Feb-2025 |
| Investor Presentation | 14-Feb-2025 |
| Financial Result Updates | 14-Feb-2025 |
| Outcome of Board Meeting | 14-Feb-2025 |
Corporate Actions of Gufic Biosciences Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Annual General Meetingdividend - Re 0.10 Per Share | 17-Sep-2024 |
| 1 | Annual General Meeting/Dividend - Re 0.10 Per Share | 21-Sep-2023 |
| 1 | Annual General Meeting/Dividend - Rs 0.10 Per Sh | 24-Aug-2022 |
| 1 | Annual General Meeting/Dividend - Rs 0.10 Per Share | 09-Sep-2021 |
| 1 | Annual General Meeting/Dividend - Rs 0.05 Per Share | 03-Nov-2020 |
| 1 | Annual General Meeting/Dividend - Rs 0.05 Per Equity Share | 20-Sep-2019 |
| 1 | Annual General Meeting/Dividend Re 0.05 Per Share | 19-Sep-2018 |
| 1 | Annual General Meeting/Dividend - Re 0.05 Per Share | 28-Aug-2017 |
| 1 | Annual General Meeting/Dividend - Re 0.05 Per Share | 19-Sep-2016 |
| 1 | Annual General Meeting/ Dividend - Re 0.05/- Per Share | 22-Sep-2015 |
| 1 | Annual General Meeting / Final Dividend - Re 0.05/- Per Share | 18-Sep-2014 |
| 1 | Annual General Meeting / Dividend - Re 0.05/- Per Share (Bc Dates Revised) | 19-Sep-2013 |
| 1 | Annual General Meeting/ Dividend Rs. 0.05 Per Share | 16-Aug-2012 |
| 1 | Annual General Meeting And Dividend Re.0.05 Per Share | 16-Sep-2011 |
| 1 | Annual General Meeting And Dividend Re.0.05 Per Share | 20-Sep-2010 |
| 1 | Agm/Div-Re.0.05 Per Share | 17-Sep-2009 |
| 1 | Agm/Dividend - 5% | 11-Dec-2008 |
| 1 | Agm/Dividend - 5% | 19-Mar-2008 |
| 1 | Agm/Div-Rs.0.16/- Per Sh | 20-Sep-2006 |
| 1 | Agm/Div-Re 0.22/- Per Sh | 22-Sep-2005 |
Board Meetings of Gufic Biosciences Limited
Financial Results of Gufic Biosciences Limited
Company Directory of Gufic Biosciences Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.gufic.com | Registered Office | Shop - 37, First Floor, Kamala Bhavan II Swami Nityanand Road Andheri East | MUMBAI |
| www.gufic.com | Transfer Agent | M/s Link Intime India Pvt Ltd. C-13, Pannalal Silk Mill Compound, | MUMBAI |
Insider Trading of Gufic Biosciences Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | JAYESH CHOKSI | 97940912 | Sell |
| 7(2) | JAYESH CHOKSI | 3967656 | Sell |
| 7(2) | Mr. Jayesh P.Choksi | 7148570 | Buy |
| 7(2) | Gufic Private Limited | 4817366 | Buy |
| 7(2) | Mrs. Vipula J. Choksi | 7148570 | Buy |
| 7(2) | Mr. Pranav J. Choksi | 0 | Sell |
| 7(2) | Zircon Teconica Private Limited (Formerly known as Zircon Finance and Leasing Private Limited) | 0 | Sell |
Annual Reports of Gufic Biosciences Limited
Investor Complaints of Gufic Biosciences Limited
Event Calendar of Gufic Biosciences Limited
| Purpose | Details |
|---|---|
| Board Meeting Adjourned | The company had informed the Exchange regarding a Board Meeting scheduled on August 20, 2009. The company has now informed the Exchange that as scheduled the Board of Directors met on August 20, 2009 to discuss, amongst other things, to consider and if thought fit to approve the annual accounts of the Company for the year ended on March 31, 2009 and at the same time also to consider and if thought fit to recommend dividend. The Board of Directors decided to adjourn the said meeting to August 24, 2009 for the want of further discussion and analysis to decide on the matters on agenda. |
| Board Meeting Adjourned | The Company has informed the Exchange that the Board of Directors meeting was first scheduled on August 20, 2009, amongst other things, to consider and if thought fit to approve the annual accounts of the Company for the year ended on March 31, 2009 and at the same time also to consider and if thought fit to recommend dividend. Board of Directors decided to adjourn the said meeting and meet again on August 24, 2009 for the want of further discussion and analysis to decide on the matters on agenda. Accordingly the Board of Directors met and discussed the matters on agenda but for the want of further clarifications from Audit Committee and Statutory Auditors of the Company Board of Directors decided to adjourn the said meeting to August 28, 2009 to decide on matters on the agenda. |
| Board Meeting Adjourned | The Company has informed the Exchange vide its letter dated May 05, 2010 that as scheduled the Board of Directors met to discuss, amongst other things, to consider and if thought fit to approve the quarterly financial results of the Company for the quarter ended on March 31, 2010. Board of Directors decided to adjourn the said meeting to May 07, 2010 for the want of further discussion and analysis and to decide on the matters on the agenda. |
| Results/Dividend | Amongst other things, to consider and if thought fit to approve the Annual Accounts of the Company for the year ended on March 31, 2010. At the same time also to consider and if thought fit to recommend dividend. |
| Board Meeting Adjourned | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on November 12, 2010 amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended September 30, 2010. The Company has now informed the Exchange that the Board of Directors decided to adjourn the said meeting to November 15, 2010 for the want of further discussion and analysis and to decide on the matters on the agenda. |
| Results/Others | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended December 31, 2010. |
| Results/Others | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended March 31, 2011. |
| Results/Dividend | Amongst other things, to consider and if thought fit to approve the Annual Accounts of the Company for the year ended on March 31, 2011. At the same time also to consider and if thought fit to recommend dividend. |
| Results/Others | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended September 30, 2011. |
| Results/Dividend | Amongst other things, to consider and if thought fit to approve the Annual Accounts of the Company for the year ended on March 31, 2012. At the same time also to consider and if thought fit to recommend dividend. |
| Dividend | Amongst other things, to consider and if thought fit to recommend dividend for the year ended on March 31, 2012. |
| Results/Others | To consider among other items, the Unaudited Financial Results for the quarter ended on September 30, 2012. |
| Results | To consider among other things, Unaudited Financial Results for the quarter ended December 31, 2012 |
| Results/Others | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended March 31, 2013. |
| Results/Dividend | Inter alia, to consider and if thought fit to approve the annual audited financial results of the Company for the year ended on March 31, 2013, to recommend dividend, if any, and any other item(s) with the permission of the chair. |
| Results/Others | (1)To consider the Unaudited Financial Results of the Company for the quarter ended June 30, 2013 (2) Fix the date of Annual General Meeting & decide to close the Books of the Company for the purpose of Annual General Meeting such other items as the board may deem fit |
| Others | Among other things, change of registered office within local limits |
| Results | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended 30th September, 2013. |
| Board Meeting Adjourned | Gufic Biosciences Limited has informed the Exchange that as scheduled the Board of Directors at it meeting held on November 14, 2013 met to discuss, amongst other things, to consider and if thought fit to approve the Unaudited financial Results of the Company for the quarter ended September 30, 2013. The Board of Directors decided to adjourn the said meeting and further discussion and analysis and to decide on the matters on the agenda on November 15, 2013. |
| Results | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended December 31, 2013. |
| Results | Inter alia to consider and approve the audited financial results of the Company for the quarter and year ended March 31, 2014. |
| Results | to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2014. |
| Others | inter alia to consider :- (i) To consider and approve the draft notice convening the Annual General Meeting of the Company. (ii) To consider and approve the Auditors Report and the Directors Report including the annexures thereon on the Audited Financial Results of the Company for the Financial Year 2013-2014. |
| Results/Others | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended September 30, 2014. |
| Results | Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended December 31, 2014. |
| Results | Inter alia to consider and approve the audited financial results of the Company for the quarter and year ended March 31, 2015. |
| Results/Dividend | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held on May 29, 2015, Inter alia to consider and approve the audited financial results of the Company for the quarter and year ended March 31, 2015. The Company has now informed the Exchange that amongst others to recommend the payment of dividend for the year ended 2014-15 if any. (Purpose revised) |
| Results/Others | amongst other things, to consider and take on record the unaudited Financial Results of the Company for the quarter ended June 30, 2015. |
| Results/Others | amongst other things, to consider and take on record the unaudited Financial Results of the Company for the quarter & half year ended September 30, 2015. |
| Results/Others | amongst other things, to consider and take on record the unaudited Financial Results of the Company for the quarter ended December 31, 2015. |
| Results/Dividend | inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2016 and recommend dividend for the financial year 2015-16, if any. |
| Results | inter alia to consider and approve unaudited financial results for the quarter ended June 30, 2016. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2016. |
| Results | inter alia, to consider and approve the unaudited Financial Results of the Company for the quarter ended December 31,2016. |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Copany for the quarter and financial year ended March 31, 2017 and recommend dividend on Equity shares for the financial year 2016-17, if any. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Amalgamation/Merger | inter alia, to consider and approve the draft scheme of amalgamation, valuation report determining the share exchange ratio and the fairness opinion for the amalgamation of M/s. Gufic Lifesciences Private Limited with the Company. |
| Results | Inter alia, to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2017. |
| Results | inter alia, to consider and approve the Un-Audited Financial Results of the Company for the quarter and Nine months ended December 31, 2017. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2018, dividend and other business matters |
| Other business matters | To consider other business matters |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Other business matters | To consider other business matters |
| Other business matters | To consider other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Other business matters | To consider other business matters |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | GUFICBIO : 30-May-2019 : The Company has informed the Exchange that a Board meeting to be held on May 29, 2019 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2019, To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Dividend | To consider dividend |
| Dividend | inter alia to consider recommendation of Final Dividend for the financial year 2018-19. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the Unaudited financial results for the period ended December 31, 2019. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Other business matters | To consider other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2020 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2021, dividend and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2021 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Gufic Biosciences Limited has informed the Exchange about Board Meeting to be held on 11-Aug-2022, inter alia, to consider and approve Unaudited Financial Results for the quarter ended June 30, 2022 |
| Financial results | Gufic Biosciences Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and recommendation of dividend, if any for the financial year 2022-23. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2023 and other business matters |
| Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| Financial Results/Other business matters | To consider and approve the Standalone and Consolidated Unaudited Financial Results for the period ended September 30, 2023 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2024, dividend and other business matters |
| Financial Results/Other business matters | To consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
| Financial Results/Other business matters | To consider and approve, inter alia, the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2024 |
Share Transfers of Gufic Biosciences Limited
Voting Results of Gufic Biosciences Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 06-FEB-2025 | Postal Ballot | Appointment of Mr. Akshya Kumar Mahapatra (DIN: 08362446) as an Independent Director of the Company. |
| 06-FEB-2025 | Postal Ballot | Revision in terms of remuneration of Mr. Pranav J. Choksi, Whole Time Director (DIN: 00001731) of the Company |
| 06-FEB-2025 | Postal Ballot | Revision in terms of remuneration of Mr. Jayesh P. Choksi, Chairman and Managing Director (DIN: 00001729) of the Company |
| 25-SEP-2024 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2024 together with Reports ofnthe Board of Directors and Auditors￢ﾀﾙ thereon and the Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2024nincluding Auditors￢ﾀﾙ Report thereon. |
| 25-SEP-2024 | AGM | Re-appointment of Mr. Pranav J. Choksin(DIN: 00001731) as Whole Time Director of the Company. |
| 25-SEP-2024 | AGM | Re-appointment of Mr. Jayesh P. Choksi (DIN: 00001729) as Chairman & Mananging Director of the Company. |
| 25-SEP-2024 | AGM | Appointment of Mr. Kamal Kishore Seth (DIN: 00194986) as an Independent Director of the Company |
| 25-SEP-2024 | AGM | Ratification of Remuneration Payable to M/s. Kale & Associates (FRN:001819), Cost Auditors for the Financial Year 2024-25 |
| 25-SEP-2024 | AGM | To appoint a director in place of Mr. Pankaj J. Gandhi (DIN: 00001858), who retires by rotation pursuant to Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment. |
| 25-SEP-2024 | AGM | To declare a Final Dividend @ 10% i.e., Re. 0.10/- per equity share of the face value of Re. 1/- each for the Financial Year ended March 31, 2024. |
| 29-SEP-2023 | AGM | To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023, including the Audited Balance Sheet as at March 31, 2023, the Statement of Profit & Loss and the Cash Flow Statement for the year ended on that date together with the Reports of Board of Directors and Auditors thereon. |
| 29-SEP-2023 | AGM | To consider and approve the issue of 33,33,000 equity shares on a Preferential basis to the Non-Promoter of the Company. |
| 29-SEP-2023 | AGM | Extension of the Gufic Biosciences Limited Employee Stock Option Plan 2023 (ￂGufic ESOP 2023ￂ) to the eligible employees of the subsidiary(ies) and/or associate company(ies), if any of the Company. |
| 29-SEP-2023 | AGM | Approval of Gufic Biosciences Limited ￂ Employee Stock Option Plan, 2023 (ￂGufic ESOP 2023ￂ) and grant of Employee Stock Options to the employees of the Company thereafter. |
| 29-SEP-2023 | AGM | Continuation of Directorship of Mr. Gopal M. Daptari (DIN: 07660662) as a Non-Executive ￂ Independent Director on attaining the age of 75 years. |
| 29-SEP-2023 | AGM | Continuation of Directorship of Mr. Jayesh P. Choksi (DIN: 00001729) as Chairman and Managing Director on attaining the age of 70 years. |
| 29-SEP-2023 | AGM | Ratification of Remuneration Payable to M/s. Kale & Associates (FRN:001819), Cost Auditors for the Financial Year 2023-24 |
| 29-SEP-2023 | AGM | To appoint a director in place of Mr. Bal Ram H. Singh (DIN: 06918085), who retires by rotation pursuant to Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment. |
| 29-SEP-2023 | AGM | To appoint a director in place of Mr. Pranav J. Choksi (DIN: 00001731), who retires by rotation pursuant to Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment. |
| 29-SEP-2023 | AGM | To declare a Final Dividend @ 10 % i.e., Re. 0.10/- per equity share of the face value of Re. 1/- each for the Financial Year ended March 31, 2023. |
FAQs on Gufic Biosciences Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.